Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Avanos Medical is a medical device manufacturer focused on chronic care and pain management products, including digestive health devices (enteral feeding tubes, gastrostomy products), respiratory health solutions (closed suction systems, airway management), and pain management systems (ON-Q surgical pain pumps). The company operates manufacturing facilities in the US, Mexico, and Asia, selling primarily through hospital group purchasing organizations and distributors. Recent severe margin compression and negative profitability suggest operational restructuring or one-time charges impacting current financials.
Avanos generates revenue through recurring consumable medical device sales to hospitals, ambulatory surgery centers, and long-term care facilities, primarily via GPO contracts and distributor networks. The 55.4% gross margin reflects manufacturing scale in disposable devices with moderate pricing power through clinical differentiation and switching costs. Revenue is driven by procedure volumes (surgeries, ICU admissions, enteral feeding patient populations) rather than capital equipment sales. The company competes on clinical outcomes data, ease-of-use features, and established relationships with hospital procurement departments. Negative net margin (-57%) and ROA (-85%) indicate significant non-operating charges, restructuring costs, or debt-related expenses masking underlying operating performance.
Hospital procedure volume trends - elective surgery rates, ICU census levels, and enteral feeding patient admissions directly drive consumable device utilization
GPO contract wins/losses and pricing negotiations - major hospital group purchasing organization contracts determine market access and pricing for 2-3 year periods
Gross margin trajectory - ability to offset input cost inflation through manufacturing efficiency, product mix shift toward higher-margin pain management products
Operating expense management and restructuring progress - given negative net margin, investors focus on path to sustainable profitability and cash generation
New product launches and clinical trial data - FDA approvals for next-generation devices or clinical studies demonstrating superior outcomes versus competitors
Hospital consolidation and GPO pricing pressure - increasing buyer concentration as hospital systems merge gives procurement departments greater negotiating leverage, compressing device pricing and margins over time
Shift to value-based care and bundled payments - hospitals increasingly scrutinize device costs within episode-based reimbursement models, favoring lower-cost alternatives unless clinical differentiation is clearly demonstrated
Regulatory compliance costs and FDA scrutiny - medical device quality system requirements, post-market surveillance obligations, and potential device recalls create ongoing operational and financial risks
Competition from larger diversified medical device companies (Medtronic, BD, Teleflex) with broader product portfolios, greater R&D budgets, and stronger hospital relationships across multiple device categories
Private label and lower-cost competitors in commodity-like enteral feeding and respiratory products where clinical differentiation is limited and price becomes primary purchasing criterion
Innovation risk - failure to develop next-generation products with demonstrable clinical advantages allows competitors to capture market share through superior technology or ease-of-use features
Negative profitability sustainability - net margin of -57% and negative ROE/ROA indicate current business model is destroying shareholder value, requiring operational turnaround or restructuring to achieve viability
Cash burn risk despite positive operating cash flow - while $0.1B operating cash flow provides near-term liquidity, sustained losses could erode cash reserves if profitability does not improve within 12-18 months
Working capital management - medical device inventory obsolescence risk if product demand shifts or new technologies render existing stock unsaleable
moderate - Hospital procedure volumes show some economic sensitivity as patients defer elective surgeries during recessions and high unemployment reduces insured populations. However, chronic care products (enteral feeding) serve non-discretionary medical needs with limited cyclicality. Pain management device utilization correlates with surgical volumes, which declined 10-15% during 2020 recession but recovered as hospitals prioritized revenue-generating procedures. Overall revenue mix weighted toward non-discretionary chronic care provides partial insulation from GDP fluctuations.
Rising interest rates have modest negative impact through two channels: (1) higher borrowing costs on any variable-rate debt or refinancing needs, though 0.17 debt/equity ratio suggests limited leverage; (2) valuation multiple compression as medical device stocks trade at premium P/E ratios that contract when risk-free rates rise, making growth less valuable. Demand-side impact is minimal as hospital capital budgets and procedure volumes show limited direct rate sensitivity. Current 1.0x P/S ratio suggests valuation already reflects distressed fundamentals.
Minimal direct credit exposure. Revenue comes from hospitals and healthcare systems with stable payment histories, though Medicaid/Medicare reimbursement policy changes can indirectly affect hospital budgets and device purchasing. Strong 2.38 current ratio indicates adequate liquidity to fund operations without credit market access. Customer credit risk is low given hospital industry payment reliability.
value/special situations - The 0.9x price/book ratio, 1.0x price/sales, and 11.7% FCF yield suggest deep value investors or distressed/turnaround specialists are primary holders. Negative profitability eliminates growth and quality investors. Recent 35% three-month rally indicates potential activist involvement or restructuring speculation. High volatility and operational uncertainty attract event-driven hedge funds betting on management changes, asset sales, or operational improvements rather than traditional long-term healthcare investors.
high - Small-cap medical device companies with operational challenges and negative profitability typically exhibit elevated volatility. The 35% three-month move followed by flat six-month performance demonstrates significant price swings. Limited analyst coverage, low trading liquidity in $0.7B market cap, and binary outcomes around restructuring success create volatility spikes around earnings releases and operational updates. Beta likely exceeds 1.3-1.5x relative to broader healthcare sector.
